Two Sigma Investments
TRVI icon

Two Sigma Investments’s Trevi Therapeutics TRVI Stock Holding History

Two Sigma Investments’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$458K Sell
38,415
-45,340
-54% -$508K ﹤0.01% 3788
2025
Q4 		$1.05M Sell
83,755
-36,175
-30% -$418K ﹤0.01% 2880
2025
Q3 		$1.1M Sell
119,930
-310
-0.3% -$2.33K ﹤0.01% 2516
2025
Q2 		$658K Buy
120,240
+2,504
+2% +$15.6K ﹤0.01% 2462
2025
Q1 		$741K Sell
117,736
-18,071
-13% -$86.2K ﹤0.01% 2334
2024
Q4 		$560K Buy
+135,807
New +$435K ﹤0.01% 2482
2023
Q2 		– Sell
-12,928
Closed -$23.9K – 3263
2023
Q1 		$23.9K Sell
12,928
-15,725
-55% -$35.6K ﹤0.01% 2836
2022
Q4 		$55.3K Sell
28,653
-50,784
-64% -$100K ﹤0.01% 2579
2022
Q3 		$122K Buy
+79,437
New +$260K ﹤0.01% 2200

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return